[en] Varicella-zoster virus (VZV) is a human alpha herpesvirus that establishes latency in sensory ganglia. Latency is characterized by the abundant expression of the immediate early protein 63 (IE63), whereas other viral proteins have not yet been detected during the quiescent phase of VZV infection. The IE63 protein is a component of the virion and is expressed very early in the infectious cycle. The IE63 protein is also expressed in skin during episodes of varicella and herpes zoster. We have evaluated the cell-mediated immune response against IE63 in naturally immune adults with a history of chickenpox, by T lymphoproliferation and cytotoxicity assays. Among donors who had T cell proliferation to unfractionated VZV Ags from infected cell extract, 59% had T cell recognition of purified IE63. The CTL response to IE63 was equivalent to CTL recognition of IE62, the major tegument component of VZV whose immunogenicity has been previously described. IgG Abs against IE63 were detected in serum from healthy immune adults. These results indicate that IE63 is an important target of immunity to VZV. T cell recognition of IE63 is likely to be involved in controlling VZV reactivation from latency.
Disciplines :
Immunology & infectious disease
Author, co-author :
Sadzot-Delvaux, Catherine ; Université de Liège - ULiège > Département des sciences de la vie > Virologie et immunologie
Kinchington, Paul R.; University of Buffalo, NY, USA
Debrus, Serge; Université de Liège - ULiège > Département des Sciences de la Vie > Virologie & Immunologie fondamentales
Rentier, Bernard ; Université de Liège - ULiège > Département de Microbiologie > Virologie fondamentale et Immunologie
Arvin, Ann M.; Stanford University, CA, USA
Language :
English
Title :
Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T-lymphocytes
Publication date :
1997
Journal title :
Journal of Immunology
ISSN :
0022-1767
eISSN :
1550-6606
Publisher :
American Association of Immunologists, Baltimore, United States - Maryland
Weller, T. H., and H. M. Witton. 1958. The etiologic agents of varicella and herpes zoster: isolation, propagation and culture characteristics in vitro. J. Exp. Med. 108:843.
Croen, K. D., J. M. Ostrove, L. J. Dragovic, and S. E. Straus. 1988. Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc. Natl. Acad. Sci. USA 85:9773.
Cohrs, R. J., M. Barbour, and D. H. Gilden. 1996. Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J. Viral. 70:2789.
Debrus, S., C. Sadzot-Delvaux, A. J. Nikkels, J. Piette, and B. Rentier. 1995. Varicella-zoster virus gene 63 encodes an immediate early protein abundantly expressed during latency. J. Virol. 69:3240.
Mahalingam, R., M. Wellish, R. Cohrs, S. Debrus, J. Piette, B. Rentier, and D. H. Gilden. 1996. Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc. Natl. Acad. Sci. USA 93:2122.
Kinchington, P. R., D. Bookey, and S. E. Turse. 1995. The transcriptional regulatory proteins encoded by varicella-zoster virus open reading frames (ORFs) 4 and 63, but not ORF61, are associated with purified virus particles. J. Virol. 69:4274.
Nikkels, A. F., S. Debrus, C. Sadzot-Delvaux, J. Piette, B. Rentier, and G. E. Piérard. 1995. Immunochemical identification of varicella-zoster virus gene 63encoded protein (IE63) and late (gE) protein on smears and cutaneous biopsies: implications for diagnostic use. J. Med. Virol. 47:342.
Hayward, A. R., and M. Herderger. 1987. Lymphocyte responses to varicella-zoster virus in the elderly. J. Clin. Immunol. 7:174.
Berger, R., G. Florent, and M. Just. 1981. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect. Immun. 32:24.
Arvin, A. M., R. B. Pollard, L. E. Ramussen, and T. C. Merigan. 1980. Cellular and humoral immunity in lymphoma patients. J. Clin. Invest. 65:869.
Sorensen, O. S., S. Haahrs, A. Moller-Larson, and K. Wildenhoff. 1980. Cell mediated and humoral immunity to herpes viruses during and after herpes zoster infections. Infect. Immun. 29:369.
Arvin, A. M., E. Kinney-Thomas, K. Shriver, C. Grose, C. M. Koropchak, E. Scranton, A. E. Wittek, and P. S. Diaz. 1986. Immunity to varicella-zoster viral glycoproteins, gpI (90/58) and gpIII (gpI18), and to a non glycosylated protein, p170. J. Immunol. 137:1346.
Arvin, A. M. 1994. The T-lymphocyte response to varicella-zoster virus and its relevance to vaccine development. Rev. Med. Virol. 4:161.
Kinchington, P. R., J. K. Houghland, A. M. Arvin, W. T. Ruyechan, and J. Hay. 1992. Varicella-zoster virus IE62 protein is a major virion component. J. Virol. 66:359.
Diaz, P. S., S. Smith, E. Hunter, and A. M. Arvin. 1989. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J. Immunol. 142:636.
Fazekas de St. Groth, S. 1982. The evaluation of limiting dilution assays. J. Immunol. Methods 49:1211.
Arvin, A. M., J. F. Moffat, and R. Redman. 1996. Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv. Virus Res. 46:263.
Giller, R. H., S. Winistorfer, and C. Grose. 1989. Cellular and humoral immunity to varicella-zoster virus glycoproteins in immune and susceptible human subjects. J. Infect. Dis. 160:919.
Sharp, M., K. Terada, A. Wilson, S. Nader, P. E. Kinchington, W. T. Ruyechan, J. Hay, and A. M. Arvin. 1992. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J. Infect. Dis. 165:852.
Zhang, Y., M. Cosyns, M. J. Levin, and A. R. Hayward. 1994. Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures. Clin. Exp. Immunol. 98:128.
Arvin, A. M., M. Sharp, S. Smith, C. M. Koropchak, P. S. Diaz, P. Kinchington, W. Ruyechan, and J. Hay. 1991. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J. Immunol. 146:257.